SecurityETP / Energy Transfer Partners, L.P. (86764L108)
IndustryNatural Gas Transmission
Total Insiders14
Total Directors8
Total Officers9

Stock Insider Trading (from SEC Form 4)

Energy Transfer Partners, L.P. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ETP / Energy Transfer Partners, L.P. insiders include WARREN KELCY L, Mason Thomas P, Perry James Richard, OWENS ROBERT W Salinas Martin, Welch Jamie, and MCCREA MARSHALL S III, Ramsey Matthew S., Grimm Michael K, Long Thomas E, Collins Ted Jr, Wright James M., Sturrock Troy, Skidmore David K, .

Insider Roster

Insider Dir Off 10% Shares Owned
Sturrock Troy SVP & CONTROLLER
X 0
Collins Ted Jr Director
X 0
Grimm Michael K Director
X 0
Long Thomas E CHIEF FINANCIAL OFFICER
X 0
WARREN KELCY L CHIEF EXECUTIVE OFFICER, Director
X X 0
Skidmore David K Director
X 0
MCCREA MARSHALL S III Chief Commercial Officer, Director
X X 0
Wright James M. General Counsel & Asst.Sec.
X 0
Ramsey Matthew S. President & COO, Director
X X 0
Perry James Richard Director
X
Mason Thomas P Sr. VP and General Counsel
X
Welch Jamie Director
X
OWENS ROBERT W President-Retail Marketing
X
Salinas Martin Chief Financial Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2017-04-28 4 Ramsey Matthew S. D D -186,006 0
2017-04-28 4 Wright James M. D D -69,874 0
2017-04-28 4 MCCREA MARSHALL S III BY: SON D I -23,640 0
2017-04-28 4 MCCREA MARSHALL S III D D -175,854 0
2017-04-28 4 Skidmore David K By: Daughter D I -129 0
2017-04-28 4 Skidmore David K D D -20,255 0
2017-04-28 4 WARREN KELCY L BY: ENERGY TRANSFER EQUITY, L.P. D I -2,571,695 0
2017-04-28 4 WARREN KELCY L D D -21,167 0
2017-04-28 4 Long Thomas E D D -74,553 0
2017-04-28 4 Grimm Michael K D D -32,742 0
2017-04-28 4 Collins Ted Jr D D -120,262 0
2017-04-28 4 Sturrock Troy D D -37,172 0
2016-12-28 4 Sturrock Troy A D 12,000 37,118
2017-01-11 4 Skidmore David K P D 35.61 3,000 20,255 721,281
2017-01-10 4 Skidmore David K By: Daughter P I 36.48 129 129 4,706
2017-01-03 4 Collins Ted Jr A D 2,780 120,262
2017-01-03 4 Collins Ted Jr A D 1,077 117,482
2016-12-08 4 Collins Ted Jr G D 10 116,405
2017-01-03 4 Grimm Michael K A D 2,780 32,742
2017-01-03 4 Grimm Michael K A D 1,077 29,962
2016-12-08 4 Grimm Michael K G D 10 28,885
2017-01-03 4 Skidmore David K A D 2,780 17,255
2017-01-03 4 Skidmore David K A D 1,077 14,475
2016-12-08 4 Skidmore David K G D 10 13,398
2016-12-29 4 MCCREA MARSHALL S III A D 153,765 756,355
2016-12-29 4 Long Thomas E A D 28,688 74,553
2016-12-29 4 Ramsey Matthew S. A D 95,625 186,006
2016-12-29 4 Wright James M. A D 23,906 69,874
2016-12-05 4 MCCREA MARSHALL S III F D 35.229 -21,658 602,590
2016-12-05 4 Long Thomas E F D 35.229 -2,500 45,865
2016-12-05 4 Long Thomas E M D 8,372 48,365
2015-12-05 4 Long Thomas E M D 8,042 39,993
2016-12-05 4 Sturrock Troy F D 35.229 -791 25,118
2016-12-05 4 Wright James M. F D 35.229 -1,653 45,968
2016-12-02 4 WARREN KELCY L P D 34.4793 70 2,592,862 89,400,067
2016-03-16 4 Skidmore David K P D 28.539 3,000 13,388 382,080
2016-03-08 4 Skidmore David K A D 1,500 10,388
2016-01-04 4 Skidmore David K A D 2,858 8,888
2015-12-30 4 Skidmore David K G D 10 6,030
2016-01-04 4 Perry James Richard A D 2,858 2,868
2015-12-30 4 Perry James Richard G D 10 10
2016-01-04 4 Grimm Michael K A D 2,858 28,875
2016-01-04 4 Grimm Michael K A D 830 26,017
2015-12-30 4 Grimm Michael K G D 10 25,187
2016-01-04 4 Collins Ted Jr A D 2,858 116,395
2016-01-04 4 Collins Ted Jr A D 830 113,537
2015-12-30 4 Collins Ted Jr G D 10 112,707
2015-12-09 4 Welch Jamie A D 29,155 69,155
2015-12-09 4 Sturrock Troy A D 7,600 25,909
2015-12-09 4 Ramsey Matthew S. A D 77,190 90,381
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

9h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

9h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

The Zacks Analyst Blog Highlights: Phillips 66, Marathon Petroleum, Oasis Petroleum, Whiting Petroleum and Continental Resources

22h zacks
Chicago, IL –June 21, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Phillips 66 (PSX - Free Report) , Marathon Petroleum Corporation (MPC - Free Report) , Oasis Petroleum Inc. (OAS - Free Report) , Whiting Petroleum Corporation (WLL - Free Report) and Continental Resources, Inc. (77-0)

Leach natgas pipe, after West Virginia blast, to resume operations early July

2018-06-19 reuters
June 19 (Reuters) - TransCanada Corp’s Columbia Gas Transmission (TCO) unit has estimated that the section of the Leach Xpress natural gas pipeline, damaged in a blast on June 7 in Marshall County, West Virginia, will resume operations early in July. (26-0)

ClearBridge Proposes MLP CEF Merger

2018-06-19 seekingalpha
This is just a quick note to our members regarding ClearBridge's proposal to merge ClearBridge American Energy MLP Fund Inc. (CBA) into ClearBridge Energy MLP Opportunity Fund Inc. (EMO), subject to approval by the stockholders of each fund. (6-1)

Energy Transfer Partners: You Have Questions

2018-06-18 seekingalpha
I explain the benefit of my approach, and why I keep telling you about it. I also explain why neither obsolescence nor anathematization of fossil fuels should concern ETP longs. (6-1)

Low Energy MLPs

2018-06-17 seekingalpha
The week started strong, with MLPs up 1.6% Monday, but then followed up with 4 straight negative days, culminating in a big Friday selloff (-2.6%). Friday was the MLP Index's worst day since March 19th, just a few days after the FERC ruling. It was also the worst week for the index since that same week in March. Unlike that week, there wasn't any big midstream news that led to the drop. The action this week was more related to the macro (i. (38-0)